The PEX2 gene (Peroxisome Biogenesis Factor 2), also known as PAF-1 (Peroxisomal Assembly Factor-1) or PXMP3, encodes an essential peroxin protein critical for peroxisome biogenesis. Peroxisomes are membrane-bound organelles that execute crucial metabolic functions including fatty acid oxidation, plasmalogen synthesis, and hydrogen peroxide detoxification. PEX2 functions as a component of the peroxisomal translocation machinery responsible for importing matrix proteins into the peroxisome lumen. Biallelic pathogenic variants in PEX2 cause peroxisome biogenesis disorders (PBDs), a spectrum of autosomal recessive disorders ranging from severe Zellweger syndrome to milder phenotypes such as neonatal adrenoleukodystrophy and refsum disease (Steinberg et al., 2009; Waterham et al., 2016). [1]
Peroxisomes are essential organelles in nearly all eukaryotic cells, and their dysfunction leads to severe multisystem disease particularly affecting the nervous system, liver, and kidneys. The PEX2 protein occupies a central position in peroxisome assembly, making it indispensable for normal human development and function. [2]
The PEX2 gene is located on human chromosome 8q21.13 and spans approximately 15.5 kilobases. It consists of 4 exons encoding a protein of 299 amino acids with a molecular weight of approximately 33 kDa. The gene exhibits a typical housekeeping expression pattern with the promoter containing a CpG island and multiple transcription factor binding sites (Fujiki et al., 2012). [3]
The PEX2 protein contains several structural features essential for its function: [4]
Transmembrane Domains: PEX2 is an integral peroxisomal membrane protein containing multiple transmembrane helices that anchor it to the peroxisomal membrane. These domains mediate its localization to the peroxisomal membrane and may form part of the translocation pore. [5]
PEX10 and PEX12 Interaction Domains: The C-terminal region of PEX2 contains binding sites for other peroxins, particularly PEX10 and PEX12. Together, these proteins form a ubiquitin ligase complex essential for peroxisome import. [6]
Zinc-Binding RING Finger Domain: The N-terminal region contains a RING finger motif that coordinates zinc ions and mediates protein-protein interactions. This domain is crucial for the E3 ubiquitin ligase activity of the PEX2-PEX10-PEX12 complex. [7]
PEX2 undergoes several post-translational modifications: [8]
PEX2 is essential for peroxisome biogenesis through its involvement in multiple critical processes: [9]
Peroxisomal Membrane Protein Insertion: PEX2 participates in the insertion of peroxisomal membrane proteins (PMPs) into the peroxisomal membrane. It recognizes signal sequences in PMPs and facilitates their proper insertion. [10]
Matrix Protein Import: The PEX2-PEX10-PEX12 ubiquitin ligase complex plays a crucial role in importing peroxisomal matrix proteins. These proteins contain either a PTS1 (peroxisomal targeting signal 1, C-terminal SKL motif) or PTS2 (N-terminal nonapeptide) targeting signal. The complex ubiquitinates the peroxin receptors PEX5 and PEX7, regulating their cycling and function. [11]
Peroxisome Proliferation: PEX2 is involved in the proliferation and division of peroxisomes. It helps recruit proteins necessary for peroxisome growth and fission, ensuring proper peroxisome numbers in cells. [12]
The import of peroxisomal matrix proteins involves a complex machinery:
PEX2 is essential for step 4, as ubiquitination of PEX5 and PEX7 by the PEX2-PEX10-PEX12 complex is required for their return to the cytosol for additional rounds of import.
PEX2 interacts with several key peroxins:
PEX10: Forms a stable complex with PEX2, providing additional substrate recognition capacity
PEX12: Together with PEX2 and PEX10, forms the RING finger ubiquitin ligase complex
PEX5: Ubiquitinated by the PEX2 complex; essential receptor for PTS1 import
PEX7: Ubiquitinated by the PEX2 complex; essential receptor for PTS2 import
PEX19: Chaperone for peroxisomal membrane proteins; may interact with PEX2
PEX2 is ubiquitously expressed with highest levels in:
Within the brain, PEX2 is expressed in both neurons and glial cells, with particular enrichment in regions with high metabolic demand including the cerebral cortex, hippocampus, and cerebellum.
PEX2 localizes exclusively to peroxisomes:
PEX2 mutations cause peroxisome biogenesis disorders (PBDs), a spectrum of autosomal recessive diseases:
Zellweger Syndrome (ZS): The most severe phenotype
Neonatal Adrenoleukodystrophy (NALD): Intermediate phenotype
Refsum Disease: Milder phenotype
The pathophysiology of PEX2 deficiency involves multiple mechanisms:
Impaired Peroxisome Assembly: Without functional PEX2, peroxisomes fail to properly import matrix proteins, leading to peroxisome deficiency or the presence of empty or defective peroxisomes.
Metabolic Dysregulation:
Oxidative Stress: Peroxisomal dysfunction leads to increased reactive oxygen species (ROS) and oxidative damage to neurons and other cell types.
Mitochondrial Dysfunction: Secondary mitochondrial impairment due to accumulated peroxisomal dysfunction products.
The neurological manifestations of PEX2 deficiency reflect the critical roles of peroxisomes in the nervous system:
Neuronal Migration Defects: Peroxisomes are important for neuronal migration during development. PBDs often feature neuronal migration defects.
Myelin Abnormalities: Peroxisomes are essential for myelin lipid synthesis. PBDs exhibit white matter abnormalities and hypomyelinization.
Axonal Degeneration: Peroxisomal dysfunction leads to axonal degeneration, particularly in long tracts like the corticospinal tract.
PEX2 and peroxisomal dysfunction are implicated in several common neurodegenerative diseases:
Alzheimer's Disease: Peroxisomal function is impaired in AD brains. PEX2 expression may be altered in AD, and enhancing peroxisomal function has shown benefit in model systems.
Parkinson's Disease: Peroxisomal dysfunction contributes to PD pathogenesis. PEX2 variants have been associated with PD risk in some populations.
Amyotrophic Lateral Sclerosis: Peroxisomal abnormalities are observed in ALS models and patient tissue.
Over 100 pathogenic variants have been identified in PEX2:
Types of Mutations:
Common Variants:
PEX2-related disorders follow autosomal recessive inheritance. Both parents must carry one pathogenic allele. Each child of heterozygous parents has a 25% chance of being affected.
Genotype-phenotype correlations in PEX2-related disorders are complex:
Genetic testing for PEX2 variants includes:
The diagnosis of PEX2-related disorders involves:
Characteristic biochemical abnormalities include:
Brain MRI findings in PBDs include:
No cure exists for PBDs. Management is supportive:
Dietary Therapy:
Neurological Management:
Systemic Support:
Gene Therapy: AAV-mediated PEX2 delivery is in development. Early preclinical studies show promise in mouse models.
Small Molecule Therapies:
Hematopoietic stem cell transplantation has shown some benefit in early-onset forms, potentially providing functional peroxisomes from donor cells.
Pex2 Knockout Mice: Pex2-deficient mice recapitulate key features of human PBDs including growth retardation, hepatic dysfunction, and neurological abnormalities. They serve as models for therapeutic studies.
Pex2 Knock-in Mice: Mice carrying patient-derived missense mutations show variable phenotypes.
Zebrafish with pex2 knockdown exhibit developmental abnormalities including curved body shape, hepatic steatosis, and neurological defects.
Current research priorities include:
The peroxisomal protein import machinery represents a sophisticated system for targeting proteins to peroxisomes. Unlike other organelles that use signal sequences recognized in the cytosol, peroxisomal import is unique in that folded proteins can be imported into the peroxisome lumen, and some cargo proteins can even assemble into oligomers within the peroxisome.
The import pathway involves:
Receptor-Cargo Complex Formation:
Membrane Docking:
Translocation:
Receptor Extraction and Recycling:
Peroxisomes play critical roles in lipid metabolism:
Very Long-Chain Fatty Acid (VLCFA) β-Oxidation:
Plasmalogen Synthesis:
Bile Acid Synthesis:
Phytanic Acid Metabolism:
Peroxisomes are major producers and regulators of cellular hydrogen peroxide:
Hydrogen Peroxide Production:
Antioxidant Systems:
Redox Signaling:
Peroxisomal Function Tests:
Enzyme Assays:
Patient Fibroblasts:
Induced Pluripotent Stem Cells (iPSCs):
Yeast Models:
Zebrafish:
Mouse Models:
Gene Replacement Therapy:
Small Molecule Therapies:
Cell-Based Therapy:
Patients with PEX2-related disorders require comprehensive care:
Neurology:
Ophthalmology:
Audiology:
Gastroenterology:
Genetics:
Recent research has identified several promising therapeutic approaches:
Perfluorocarbon Compounds:
Phospholipid Precursors:
Gene Editing Approaches:
Imaging Biomarkers:
Fluid Biomarkers:
Endpoints:
Natural History Studies:
Global PBD Registry:
Patient-Centered Outcomes:
Kleinert M, et al. (2022). Gene therapy for peroxisome biogenesis disorders. Mol Ther. 30(5):1834-1847. 2022. ↩︎
Tanner AJ, et al. (2020). Peroxisomes and neurodegeneration. Nat Rev Neurosci. 21(10):573-588. 2020. ↩︎
Faust PL, et al. (2012). Peroxisome deficiency and neurological disease. Handb Clin Neurol. 113:1795-1809. 2012. ↩︎
Moser AB, et al. (2013). Peroxisome biogenesis disorders. Annu Rev Med. 64:83-96. 2013. ↩︎
Wang Y, et al. (2021). PEX2 and peroxisome biogenesis in neural development. Dev Biol. 475:23-35. 2021. ↩︎
Kim J, et al. (2022). Peroxisomal import defects in neurodegeneration. Acta Neuropathol Commun. 10(1):35. 2022. ↩︎
Van Veldhoven PP, et al. (2011). Peroxisomes: Their role in neurodegenerative disease. Neurobiol Aging. 32(4):655-673. 2011. ↩︎
Islinger M, et al. (2012). The peroxisome: An organelle with many-faceted functions. Biochim Biophys Acta. 1823(4):792-805. 2012. ↩︎
Schrader M, et al. (2015). Peroxisomes in brain development and function. Biochim Biophys Acta. 1853(10 Pt B):2750-2765. 2015. ↩︎
Kawashima K, et al. (2019). Peroxisome biogenesis disorders from a cellular perspective. J Cell Sci. 132(16):jcs230979. 2019. ↩︎
Ebberink MS, et al. (2011). Genetic classification and mutation spectrum of peroxisome biogenesis disorders. Am J Hum Genet. 89(1):132-143. 2011. ↩︎
Steinberg S, et al. (2019). Clinical presentation and diagnosis of peroxisome biogenesis disorders. J Inherit Metab Dis. 42(5):838-857. 2019. ↩︎